Natera Updates On Patent Ruling In Litigation With NeoGenomics

August 29, 2025 — 06:09 pm EDT

Written by RTTNews.com for RTTNews

(RTTNews) - Natera, Inc. (NTRA), a leader in cell-free DNA and precision medicine, reported that the U.S. District Court for the Middle District of North Carolina has invalidated certain claims in two patents Natera asserted against NeoGenomics' RaDaR v1.1 test.

The company is reviewing its options, including a potential appeal or additional enforcement actions under other patents.

The ruling does not affect U.S. Patent No. 11,519,035, which supported prior injunctions that removed NeoGenomics' RaDaR v1.0 product from the market. Natera emphasized its portfolio of over 500 issued or pending patents and reaffirmed its commitment to safeguarding its investments in innovation.

Natera stated that the invalidated patents are separate from its '035 patent, which remains valid and enforceable. The company reiterated its intention to defend its intellectual property and pursue measures to protect its technological advancements.

NTRA currently trades at $168.25 or 0.19% higher on the NasdaqGS.

RTTNews

Founded in the late 1990s by Andrew Mariathasan in New York, with the goal of covering Wall Street for a new generation of investors, RTTNews has expanded steadily over the years to become a trusted provider of content for a wide array of subjects across several platforms. RTT's Financial Newswire is relied upon by some of the world's largest financial institutions, including banks, brokerages, trading platforms and financial exchanges.

Natera Updates On Patent Ruling In Litigation With NeoGenomics

Tags

Latest Articles